Physician

Kush Sachdeva, MD

According to 2025 Medicare claims, Kush Sachdeva, MD (NPI: 1750372686) practices hematology/oncology in the Vineland, NJ market, with the plurality of this provider's patient population coming from Cumberland, NJ. This provider's primary affiliated billing organization is SOUTHERN ONCOLOGY HEMATOLOGY ASSOC (NPI: 1144211087; TIN: 222182145) and primary practice location at 08360-7059.

Sachdeva's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 510 traditional Medicare patients, billed 169,817 HCPCS/CPT codes, and received $2,257,395 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,092 prescription claims across 193 beneficiaries totaling $4,136,856 in drug costs, led by Keytruda (Pembrolizumab). 2017 DME data shows 37 claims. Open Payments data shows 135 records totaling $71,560. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,346,252 to $4,136,856. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $3,141 to $744.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,037	206,185	$2,295,215
2016	928	243,284	$2,523,255
2017	808	172,204	$2,202,286
2018	745	178,947	$2,692,431
2019	609	109,354	$1,798,001
2020	578	162,689	$2,429,150
2021	598	200,491	$2,265,327
2022	454	124,662	$2,007,596
2023	433	114,416	$1,830,523
2024	510	169,817	$2,257,395

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	184	991	$1,346,252
2016	192	1,248	$1,910,421
2017	181	964	$1,341,222
2018	199	991	$1,380,265
2019	206	1,130	$2,390,129
2020	211	1,047	$2,143,186
2021	190	819	$2,307,894
2022	154	707	$2,810,809
2023	163	859	$3,019,033
2024	193	1,092	$4,136,856

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	12	$226
2016	N/R	N/R	N/R
2017	N/R	37	$966
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	80	319	$117
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	230	559	$105
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	234	499	$78
96372	Injection of drug or substance under skin or into muscle	112	429	$13
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	265	910	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Keytruda	Pembrolizumab	49	1,029	$539,541
Neulasta	Pegfilgrastim	50	1,204	$398,672
Darzalex Faspro	Daratumumab-Hyaluronidase-Fihj	20	547	$324,662
Pomalyst	Pomalidomide	11	308	$251,188
Revlimid	Lenalidomide	14	371	$225,052

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	134	$2,788	Alexion Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$68,772	Boehringer Ingelheim Pharma GmbH & Co.KG
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kush Sachdeva, MD?

Tedicare shows public-source Medicare data for Kush Sachdeva, MD (NPI 1750372686), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kush Sachdeva, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Kush Sachdeva, MD?

Kush Sachdeva, MD is linked to SOUTHERN ONCOLOGY HEMATOLOGY ASSOC (billing NPI 1144211087) in the available physician profile data.

Does Kush Sachdeva, MD have Open Payments data?

Kush Sachdeva, MD has 135 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.